Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 9;38(5):598-601.
doi: 10.1016/j.ccell.2020.09.019. Epub 2020 Oct 2.

Cytokine Storms in Cancer and COVID-19

Casmir Turnquist  1 , Bríd M Ryan  2 , Izumi Horikawa  2 , Brent T Harris  3 , Curtis C Harris  4
Affiliations

Cytokine Storms in Cancer and COVID-19

Casmir Turnquist et al. Cancer Cell. .

Abstract

During the COVID-19 pandemic, research on "cytokine storms" has been reinvigorated in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investigation, with several ongoing clinical trials. We lay a framework for understanding the role of IL-6 in the context of cancer research and COVID-19 and suggest how lessons learned from cancer research may impact SARS-CoV-2 research and vice versa.

PubMed Disclaimer

Figures

Figure 1
Figure 1
“Cytokine Storms” in Lung Cancer Tumorigenesis, CAR T Therapy, and SARS-CoV-2 Infection and Repurposed Anti-IL-6 Therapeutics for COVID-19 (A) IL-6 plays a key role in the detrimental systemic hyperactivated immune status characteristic of “cytokine storms.” IL-6 accumulates via other cytokines, including TNF-α. In lung cancer, it is produced by lung epithelial cells and exhausted tumor-associated CD8+ T lymphocytes. IL-6 acts on lung epithelial cells in inflammatory environments such as tobacco smoking. IL-6 is also a driver of CAR T-induced “cytokine storm” as a toxic therapy side effect and is associated with disease severity in COVID-19, where it is produced by monocyte-derived and recruited macrophages. In all of these settings, IL-6 is key to disease pathogenesis and a hallmark of poor prognosis. (B) BKT inhibition (Acalabrutinib) inhibits NF-κB signaling and results in decreased IL-6 production. Corticosteroids (Dexamethasone) inhibit TNF-α-mediated IL-6 mRNA expression and protein secretion by decreasing IL-6 mRNA stability. IL-6R monoclonal antibodies (Tocilizumab, Siltuximab) dampen both the classic and the trans-signaling IL-6 pathways to suppress IL-6-JAK-STAT signaling. All of these approaches are currently under investigation in clinical trials to treat COVID-19. Figures were created using biorender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217. - PubMed
    1. Biran N., Ip A., Ahn J., Go R.C., Wang S., Mathura S., Sinclaire B.A., Bednarz U., Marafelias M., Hansen E., et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2:e603–e612. - PMC - PubMed
    1. Bost P., Giladi A., Liu Y., Bendjelal Y., Xu G., David E., Blecher-Gonen R., Cohen M., Medaglia C., Li H., et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020;181:1475–1488. - PMC - PubMed
    1. Choy E.H., De Benedetti F., Takeuchi T., Hashizume M., John M.R., Kishimoto T. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 2020;16:335–345. - PMC - PubMed
    1. Del Valle D.M., Kim-Schulze S., Huang H. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643. - PMC - PubMed

LinkOut - more resources